12:58 PM EDT, 05/15/2024 (MT Newswires) -- Bausch Health ( BHC ) announced updates in the Xifaxan patent litigation with Norwich, noting that both parties have filed petitions for panel rehearing or rehearing en banc in the Appellate Court. BHC expects a decision on the rehearing request within the next three months.

The Appellate Court has rarely granted a rehearing, and a change in the outcome is even less probable, but this has happened in the past during the Gilenya patent litigation, says RBC analyst Douglas Miehm.

Bausch Health ( BHC ) also said that it has received a new Para IV certification from Norwich to market a generic version of Xifaxan for

the treatment of IBS-D in adults. BHC believes that it could get a new 30-month stay if it sues Norwich within 45 days following

the receipt on the notice.

While BHC could seek a 30-month stay on the new ANDA filing by Norwich, it would likely be intensely contested, Miehm adds.

According to RBC, lawyers at Bloomberg Intelligence have previously noted a two- to four-year time frame for additional patent litigation.

Bausch Health ( BHC ) is rated Sector Perform, with a US$10 target.

Price: 9.67, Change: -0.07, Percent Change: -0.72